Skip to Content
We are here to provide the care you need. Our centers of care are experiencing high volumes and long wait times. Learn about your care options. Currently, no routine visitors are allowed at the hospital or at any outpatient care centers.

Ophthalmic Surgery Trials

A Phase 2/3, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION)
Aims:  There is currently no approved treatment for NAION. Participants in this study will be assigned to receive an injection of an investigational drug or sham procedure to one eye over a four-month treatment period. The drug is being studied to determine its ability to treat vision loss that can occur in NAION.
Diagnosis:  Non-arteritic anterior ischemic optic neuropathy (NAION)
Principal Investigator: John Pula, MD
IRB Approval Number: EH16-164
Sponsor:  Quark Pharmaceuticals, Inc.
Contact:  Interested patients may contact Mira Shiloach at 847.657.1750, mshiloach@northshore.org
Open to Enrollment:  Yes

Zoster Eye Disease Study (ZEDS): A multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.
Aims: This is a multi-center randomized clinical trial to look at whether long-term treatment with Valacyclovir versus placebo will be effective in decreasing eye disease and/or severe pain in patients with herpes zoster ophthalmicus
Diagnosis:  Eye disease from shingles affecting the cornea, within the past year
Principal Investigator: Marian Macsai, MD
IRB Approval Number: EH17-188
Sponsor:   National Eye Institute of the NIH
Contact:  Interested patients may contact Mira Shiloach at 847.657.1750, mshiloach@northshore.org
Open to Enrollment:  Yes

A Pilot Study For Efficacy and Safety of Glanatec® Ophthalmic Solution 0.4% on Corneal Edema And Endothelial Cell Counts in Subjects with Fuchs Endothelial Dystrophy
Aims: To investigate whether the drug Glanatec ® (which is approved in Japan for glaucoma and ocular hypertension) can be used in patients with Fuchs endothelial dystrophy who have had a Descemet stripping procedure without a corneal cell transplant
Diagnosis:  Fuchs Endothelial Dystrophy- visually significant
Principal Investigator: Marian Macsai, MD
IRB Approval Number: EH17-320
Sponsor: NorthShore University HealthSystem Foundation, Research and Education Fund
Contact:  Interested patients may contact Mira Shiloach at 847.657.1750, mshiloach@northshore.org
Open to Enrollment:  Yes

A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants with Previous NAION
Aims: To evaluate the efficacy and safety of RPh201 (a purified plant extract), administered twice weekly over 26 weeks, on visual function in patients with prior NAION.
Diagnosis:  Nonarterteritic anterior ischemic optic neuropathy (NAION) in the past 5 years.
Principal Investigator: John Pula, MD
IRB Approval Number: EH18-294
Sponsor: Regenera Pharma, Ltd.
Contact:  Interested patients may contact Mira Shiloach at 847.657.1750, mshiloach@northshore.org
Open to Enrollment:  Yes